Establishment of an RNA polymerase II-driven reverse genetics system for Nipah virus strains from Malaysia and Bangladesh.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 08 2019
01 08 2019
Historique:
received:
25
10
2018
accepted:
19
07
2019
entrez:
3
8
2019
pubmed:
3
8
2019
medline:
6
11
2020
Statut:
epublish
Résumé
Nipah virus (NiV) has emerged as a highly lethal zoonotic paramyxovirus that is capable of causing a febrile encephalitis and/or respiratory disease in humans for which no vaccines or licensed treatments are currently available. There are two genetically and geographically distinct lineages of NiV: NiV-Malaysia (NiV-M), the strain that caused the initial outbreak in Malaysia, and NiV-Bangladesh (NiV-B), the strain that has been implicated in subsequent outbreaks in India and Bangladesh. NiV-B appears to be both more lethal and have a greater propensity for person-to-person transmission than NiV-M. Here we describe the generation and characterization of stable RNA polymerase II-driven infectious cDNA clones of NiV-M and NiV-B. In vitro, reverse genetics-derived NiV-M and NiV-B were indistinguishable from a wildtype isolate of NiV-M, and both viruses were pathogenic in the Syrian hamster model of NiV infection. We also describe recombinant NiV-M and NiV-B with enhanced green fluorescent protein (EGFP) inserted between the G and L genes that enable rapid and sensitive detection of NiV infection in vitro. This panel of molecular clones will enable studies to investigate the virologic determinants of henipavirus pathogenesis, including the pathogenic differences between NiV-M and NiV-B, and the high-throughput screening of candidate therapeutics.
Identifiants
pubmed: 31371748
doi: 10.1038/s41598-019-47549-y
pii: 10.1038/s41598-019-47549-y
pmc: PMC6671980
doi:
Substances chimiques
RNA Polymerase II
EC 2.7.7.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11171Références
J Virol Methods. 2003 Feb;107(2):229-36
pubmed: 12505638
Virol J. 2018 Mar 27;15(1):56
pubmed: 29587789
J Infect Dis. 2000 May;181(5):1755-9
pubmed: 10823779
Sci Transl Med. 2012 Aug 8;4(146):146ra107
pubmed: 22875827
Emerg Infect Dis. 2014 Jun;20(6):1064-6
pubmed: 24865545
Virology. 2008 Jan 5;370(1):33-44
pubmed: 17904180
J Virol. 2010 Oct;84(19):9831-9
pubmed: 20660198
Nat Commun. 2014 Nov 18;5:5342
pubmed: 25405640
Lancet. 1999 Oct 9;354(9186):1257-9
pubmed: 10520635
Emerg Infect Dis. 2007 Jul;13(7):1031-7
pubmed: 18214175
J Virol. 2016 Jun 24;90(14):6326-6343
pubmed: 27147733
Vector Borne Zoonotic Dis. 2012 Jan;12(1):65-72
pubmed: 21923274
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16508-13
pubmed: 17053073
Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11030-5
pubmed: 15258291
PLoS One. 2009 Jul 28;4(7):e6367
pubmed: 19636378
J Virol. 2015 Jan 15;89(2):1242-53
pubmed: 25392218
Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W176-80
pubmed: 15215375
Emerg Infect Dis. 2004 Dec;10(12):2082-7
pubmed: 15663842
PLoS Pathog. 2009 Oct;5(10):e1000642
pubmed: 19888339
Mol Syst Biol. 2011 Oct 11;7:539
pubmed: 21988835
Can J Neurol Sci. 2002 Feb;29(1):83-7
pubmed: 11858542
Sci Transl Med. 2011 Oct 19;3(105):105ra103
pubmed: 22013123
Rev Med Virol. 1999 Apr-Jun;9(2):83-99
pubmed: 10386336
Antiviral Res. 2003 Jan;57(1-2):113-9
pubmed: 12615307
J Clin Virol. 2008 Dec;43(4):396-400
pubmed: 18835214
PLoS One. 2012;7(10):e47790
pubmed: 23094089
Ann Neurol. 2001 Jun;49(6):810-3
pubmed: 11409437
Nature. 2006 Jan 19;439(7074):344-8
pubmed: 16327776
Rev Sci Tech. 2000 Apr;19(1):160-5
pubmed: 11189713
Emerg Infect Dis. 2006 Feb;12(2):235-40
pubmed: 16494748
Arch Virol. 2011 Jun;156(6):979-86
pubmed: 21327786
J Virol. 2009 Aug;83(16):7828-41
pubmed: 19515782
Emerg Infect Dis. 2011 May;17(5):907-9
pubmed: 21529409
J Virol. 2012 Oct;86(20):10999-1012
pubmed: 22855479
Emerg Infect Dis. 2013 Jan;19(1):51-60
pubmed: 23261015
Emerg Infect Dis. 2014 Mar;20(3):372-9
pubmed: 24572697
J Gen Virol. 2016 Apr;97(4):839-843
pubmed: 26781134
J Comp Pathol. 2007 May;136(4):266-72
pubmed: 17498518
Microbes Infect. 2002 Feb;4(2):145-51
pubmed: 11880045
Antiviral Res. 2018 May;153:101-113
pubmed: 29601894
Emerg Infect Dis. 2012 Feb;18(2):248-55
pubmed: 22304936
J Infect Dis. 2018 Nov 22;218(suppl_5):S466-S470
pubmed: 29878131
Nat Commun. 2015 Jun 24;6:7483
pubmed: 26105519
Virol J. 2013 Mar 25;10:95
pubmed: 23521919
J Virol. 1999 Jan;73(1):152-60
pubmed: 9847317
Sci Rep. 2016 Aug 03;6:30916
pubmed: 27484128
mSphere. 2017 Mar 29;2(2):
pubmed: 28405630
J Comp Pathol. 2002 Feb-Apr;126(2-3):124-36
pubmed: 11945001
Emerg Infect Dis. 2005 Oct;11(10):1594-7
pubmed: 16318702
Emerg Infect Dis. 2001 May-Jun;7(3):439-41
pubmed: 11384522
Biotechniques. 2010 Jun;48(6):463-5
pubmed: 20569222
Science. 2000 May 26;288(5470):1432-5
pubmed: 10827955
J Virol. 2006 Jun;80(12):5708-15
pubmed: 16731909
Antiviral Res. 2014 Jun;106:53-60
pubmed: 24680955
Antiviral Res. 2013 Oct;100(1):38-43
pubmed: 23911335
PLoS Negl Trop Dis. 2013;7(1):e2024
pubmed: 23342177
J Virol Methods. 2006 Mar;132(1-2):59-68
pubmed: 16226320
Nat Commun. 2012 Apr 24;3:796
pubmed: 22531181
N Engl J Med. 2000 Apr 27;342(17):1229-35
pubmed: 10781618
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Emerg Infect Dis. 2009 Aug;15(8):1229-35
pubmed: 19751584
Am J Pathol. 2003 Nov;163(5):2127-37
pubmed: 14578210
Emerg Infect Dis. 2015 Feb;21(2):328-31
pubmed: 25626011
Microbes Infect. 2001 Apr;3(4):279-87
pubmed: 11334745
PLoS One. 2010 May 18;5(5):e10690
pubmed: 20502528
PLoS Pathog. 2012;8(8):e1002836
pubmed: 22879820
PLoS One. 2010 Sep 15;5(9):e12709
pubmed: 20856799
MMWR Morb Mortal Wkly Rep. 1999 Apr 30;48(16):335-7
pubmed: 10366143
J Gen Virol. 2001 Sep;82(Pt 9):2151-2155
pubmed: 11514724